Ah well, Quarterly due out by next Tuesday! I'm counting on ADO still having $5 million in the "kitty" which will stand us "in good stead" leading into the next sign-ons.
I reckon that staff costs and advertising will be up a "smigen" on last quarter with revenue down a bit to account for the eBioscience upfront payment.
There has only been one formal ASX announcement (the US Patent) since the last Quarterly, but we know from twitter that a lot has been going on behind the scenes.
Anteo's cash position is far better than most biotechs that I follow, given also that ADO is heading towards a cash flow positive situation.
Let the Games begin (lol)!
Regards,
Goggo
moment of truth, page-39
Add ADO (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $49.36M | |||
| Open | High | Low | Value | Volume |
| 2.0¢ | 2.1¢ | 2.0¢ | $21.31K | 1.053M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 23 | 5730857 | 2.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.1¢ | 724070 | 5 |
View Market Depth
| Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
| ADO (ASX) Chart |